Vascular Biogenics Current Ratio 2013-2021 | VBLT

Vascular Biogenics current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Vascular Biogenics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.06B $0.01B 6.74
2021-03-31 $0.04B $0.01B 5.55
2020-12-31 $0.03B $0.01B 4.29
2020-09-30 $0.04B $0.01B 5.16
2020-06-30 $0.04B $0.01B 6.41
2020-03-31 $0.03B $0.01B 4.11
2019-12-31 $0.04B $0.01B 4.36
2019-09-30 $0.04B $0.01B 5.49
2019-06-30 $0.05B $0.01B 6.45
2019-03-31 $0.05B $0.01B 8.35
2018-12-31 $0.05B $0.01B 10.83
2018-09-30 $0.06B $0.01B 11.46
2018-06-30 $0.06B $0.01B 10.44
2018-03-31 $0.05B $0.01B 6.59
2017-12-31 $0.06B $0.01B 7.72
2017-09-30 $0.03B $0.01B 5.87
2017-06-30 $0.04B $0.01B 6.48
2017-03-31 $0.04B $0.01B 9.22
2016-12-31 $0.05B $0.01B 9.73
2016-09-30 $0.05B $0.00B 13.12
2016-06-30 $0.05B $0.00B 12.74
2016-03-31 $0.03B $0.00B 8.58
2015-12-31 $0.04B $0.00B 9.28
2015-09-30 $0.03B $0.01B 5.57
2015-06-30 $0.03B $0.00B 9.68
2015-03-31 $0.04B $0.00B 11.96
2014-12-31 $0.04B $0.00B 12.88
2014-09-30 $0.01B $0.01B 1.50
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.01B $0.00B 2.68
2013-09-30 $0.00B 0.00
2012-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.147B $0.001B
Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76